PNPLA3 rs11655505: Liver Fat Predisposition and Genotypes

What each genotype means

Genomic Location and Variant Characteristics

The single nucleotide polymorphism rs11655505 is positioned within an intron of the PNPLA3 gene on chromosome 22q13. Because it resides in an intronic non-coding region, it does not alter the amino acid sequence of the encoded protein directly. Instead, research indicates that rs11655505 often serves as a genomic tag or proxy variant. It exists in substantial linkage disequilibrium with rs738409, the well-characterized missense mutation (p.I148M) within the same locus that drives cellular lipid alterations. In genetic epidemiology studies, intronic variants such as rs11655505 frequently show up alongside primary causative markers during genome-wide association scans. While cataloged under health predisposition for steatotic liver disease, direct functional evidence demonstrating that rs11655505 independently alters gene transcription or splicing is limited. It is therefore primarily interpreted as an inherited co-segregating marker within the PNPLA3 risk haplotype.

The Biological Role of the PNPLA3 Gene

The PNPLA3 gene encodes patatin-like phospholipase domain-containing protein 3, also known as adiponutrin. This enzyme localizes to the surface of lipid droplets within hepatocytes (liver cells) and adipose tissue. Under standard physiological conditions, adiponutrin exerts hydrolase activity against triglycerides and retinyl esters, aiding in lipid droplet remodeling and fat mobilization. When the locus is perturbed—most notably by the co-inherited I148M missense alteration—the mutated protein accumulates on the lipid droplet surface and resists normal proteasomal degradation. This impairs the normal hydrolysis of intracellular fats, effectively trapping triglycerides inside liver cells. Over time, persistent lipid accumulation can trigger cellular stress, inflammatory recruitment, and fibrogenesis, driving simple steatosis toward metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH).

Evidence Strength and Clinical Associations

The evidence supporting the general role of the PNPLA3 locus in liver fat accumulation and progressive fibrosis is exceptionally robust across global populations, having been replicated in numerous genome-wide association studies. However, the specific evidence attributing independent causal risk to rs11655505 itself remains classified as limited. In statistical models that adjust for the prominent rs738409 (p.I148M) missense variant, intronic markers like rs11655505 typically show minimal residual independent effect on hepatic triglyceride levels or liver enzyme elevations. Instead, its clinical significance comes almost entirely from its co-inheritance pattern on risk haplotypes. Studies evaluating chronic liver disease risk have demonstrated that when co-inherited with causal PNPLA3 alleles, individuals carry higher average odds of steatosis, elevated alanine aminotransferase (ALT), and histological fibrosis progression, though these effects are heavily amplified by metabolic comorbidities like obesity.

Ancestry and Global Population Patterns

Because rs11655505 mirrors the broader haplotypic variation observed across the PNPLA3 gene region, its allele frequencies vary substantially across major ancestral backgrounds. In populations of European descent, the minor allele frequency is moderate, hovering around 0.22. In contrast, frequencies are substantially higher among Admixed American and Hispanic cohorts, where minor allele frequencies often reach approximately 0.45 to 0.50. These frequencies directly parallel the epidemiological distribution of steatotic liver disease across continental populations, where populations with substantial indigenous American ancestry carry higher baseline genetic susceptibility. Conversely, the variant frequency is typically lowest in cohorts of African ancestry. Understanding these population-level baselines is essential to prevent false positives and over-interpretation in multi-ethnic genomic screening panels.

Navigating Personal Genetic Information

Identifying an individual genotype at rs11655505 provides educational insight into inherited genomic architecture, but it does not constitute a clinical diagnosis of fatty liver disease or cirrhosis. Complex metabolic conditions are polygenic and profoundly modulated by environmental exposures, dietary intake, insulin sensitivity, and alcohol consumption. A predisposition does not guarantee that fat will accumulate in the liver, just as a low-risk genotype does not provide total immunity from metabolic liver injury. Individuals curious about their liver health or metabolic parameters should focus on established preventative measures, such as maintaining a balanced diet, engaging in regular physical exercise, and minimizing alcohol intake. Any questions regarding liver enzymes, metabolic markers, or diagnostic imaging should always be discussed directly with a qualified healthcare professional.

Frequently asked questions

Sources & further reading

Related variants in PNPLA3